TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07665515: A Phase I/Ib, Multi-centre, Open-label Study to Evaluate the Safety, Tolerability, and Immunogenicity of CryptiVax-1001, a mRNA Lipid Nanoparticle Therapeutic Cancer Vaccine, in Participants With FIGO Stage III-IV High-G

Sponsor: Epitopea Ltd · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 50 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,100,016

Rescue Site Savings

+$4,680,984

Unlock Full NCT07665515 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07665515 Rescue Dossier →